New Risk • May 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 82% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Market cap is less than US$10m (₪26.3m market cap, or US$9.04m). Minor Risk Revenue is less than US$5m (US$2.9m revenue). New Risk • Mar 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.3m free cash flow). Share price has been highly volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$10m (₪15.5m market cap, or US$5.02m). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (US$2.9m revenue). Reported Earnings • Mar 11
Full year 2025 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2024) Full year 2025 results: US$0.15 loss per share (improved from US$0.39 loss in FY 2024). Revenue: US$2.89m (up 9.8% from FY 2024). Net loss: US$3.83m (loss narrowed 59% from FY 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Announcement • Feb 13
HomeBiogas Ltd, Annual General Meeting, Mar 18, 2026 HomeBiogas Ltd, Annual General Meeting, Mar 18, 2026. Location: co. offices, Israel New Risk • Feb 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪30.5m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Market cap is less than US$10m (₪30.5m market cap, or US$9.78m). Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (US$2.9m revenue). New Risk • Sep 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (₪46.3m market cap, or US$13.9m). Announcement • Sep 19
HomeBiogas Ltd, Annual General Meeting, Oct 23, 2025 HomeBiogas Ltd, Annual General Meeting, Oct 23, 2025. Location: co. offices, Israel New Risk • Aug 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (US$2.6m revenue). Market cap is less than US$100m (₪39.2m market cap, or US$11.5m). Announcement • Jul 23
HomeBiogas Ltd has filed a Follow-on Equity Offering in the amount of ILS 2.981039 million. HomeBiogas Ltd has filed a Follow-on Equity Offering in the amount of ILS 2.981039 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,710,035
Price\Range: ILS 1.1
Transaction Features: Subsequent Direct Listing Reported Earnings • Apr 01
Full year 2024 earnings released: US$0.39 loss per share (vs US$0.50 loss in FY 2023) Full year 2024 results: US$0.39 loss per share (improved from US$0.50 loss in FY 2023). Revenue: US$2.63m (down 46% from FY 2023). Net loss: US$9.42m (loss narrowed 17% from FY 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Announcement • Mar 24
HomeBiogas Ltd to Report Q4, 2024 Results on Mar 27, 2025 HomeBiogas Ltd announced that they will report Q4, 2024 results on Mar 27, 2025 New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (₪31.1m market cap, or US$8.64m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (US$3.0m revenue). New Risk • Jan 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪35.4m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (₪35.4m market cap, or US$9.82m). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (US$3.0m revenue). Announcement • Nov 26
HomeBiogas Ltd, Annual General Meeting, Dec 29, 2024 HomeBiogas Ltd, Annual General Meeting, Dec 29, 2024. Location: co. offices, Israel New Risk • Nov 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (₪12.6m market cap, or US$3.39m). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (US$3.0m revenue). New Risk • Jul 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪36.1m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 37% per year over the past 5 years. Market cap is less than US$10m (₪36.1m market cap, or US$9.93m). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (US$4.8m revenue). Announcement • Jun 27
HomeBiogas Ltd, Annual General Meeting, Jul 17, 2024 HomeBiogas Ltd, Annual General Meeting, Jul 17, 2024. Location: co. offices, Israel Board Change • May 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Outside Director Limor Wiesel was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Apr 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 37% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (US$4.8m revenue). Market cap is less than US$100m (₪84.8m market cap, or US$22.3m). Announcement • Mar 29
HomeBiogas Ltd, Annual General Meeting, May 01, 2024 HomeBiogas Ltd, Annual General Meeting, May 01, 2024, at 16:00 Israel Standard Time. Announcement • Mar 21
HomeBiogas Ltd to Report Q4, 2023 Results on Mar 21, 2024 HomeBiogas Ltd announced that they will report Q4, 2023 results on Mar 21, 2024 New Risk • Feb 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). Earnings have declined by 46% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₪76.3m market cap, or US$21.2m). Announcement • Aug 11
HomeBiogas Ltd to Report Q2, 2023 Results on Aug 14, 2023 HomeBiogas Ltd announced that they will report Q2, 2023 results on Aug 14, 2023 New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$13m free cash flow). Earnings have declined by 56% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Revenue is less than US$5m (US$4.7m revenue). Market cap is less than US$100m (₪65.8m market cap, or US$18.0m). New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$13m free cash flow). Earnings have declined by 56% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Revenue is less than US$5m (US$4.7m revenue). Market cap is less than US$100m (₪65.8m market cap, or US$18.0m). Reported Earnings • Mar 18
Full year 2022 earnings released: US$0.77 loss per share (vs US$0.44 loss in FY 2021) Full year 2022 results: US$0.77 loss per share (further deteriorated from US$0.44 loss in FY 2021). Revenue: US$4.70m (up 89% from FY 2021). Net loss: US$15.2m (loss widened 83% from FY 2021). Reported Earnings • Mar 28
Full year 2021 earnings released: US$0.44 loss per share (vs US$0.42 loss in FY 2020) Full year 2021 results: US$0.44 loss per share (down from US$0.42 loss in FY 2020). Net loss: US$8.31m (loss widened 97% from FY 2020).